INTRODUCTION
Hepatocellular carcinoma (HCC) also known as malignant hepatoma, accounts for most of the liver cancers. HCC is the most common liver cancer. It is 5th most common tumor and third leading cause of cancer deaths world wide1. Although this disease is prevalent in Asia and Africa but its incidence is continuously increasing throughout the rest of world.2 Patients with Hepatitis B or C are at higher risk to suffer from HCC, even without transition to cirrhosis. Most of patients with chronic liver disease may progress to HCC (70-90%).3 Early diagnosis of HCC could be done by regular surveillance of high risk population using biochemical markers and ultrasonography (USG). Up till now α-fetoprotein (AFP) has been widely used as tumor marker for detection and monitoring of HCC. 4 AFP is a single chain glycoprotein. It is produced in early fetal life in the yolk sac, gastrointestinal tract and liver. AFP is as major serum protein during fetal life but its level decreases rapidly towards birth. Its level is increased during pregnancy and also in some benign and malignant conditions including HCC. Therefore it has been used as tumor marker of HCC. High AFP level in blood has been associated with larger size tumor, bilobar involvement, diffuse type tumors and portal vein tumor thrombus.
This study was aimed to verify the correlation between serum AFP level and tumor size in patients with HCC in a tertiary care hospital. 
MATERIALS AND METHODS

Study Design
Methods
Five ml venous blood was drawn aseptically from anterior cubital vain and allowed to clot. Serum was obtained by centrifugation and refrigerated until tested. Serum AFP level, anti HCV and Hbs Ag were measured using standard ELISA kits. Manufacturers instructions were strictly followed during testing.
To study correlation between serum AFT level and tumor size, study population was divided into two groups based on tumor size and AFP level. For the purpose of statistical analysis each group was further divided into three subgroups depending on tumor size: Group I = < 5cm, Group II = 5-10 cm, Group III = > 10 cm.
RESULTS
A total number of 45 HCC cases were enrolled in the study. The majority of patients were men (32 males, 13 females). Mean age was 52.0±11.1 years (range 30-90). Thirty-three patients (73.3%) were seropositive for anti HCV, six (13.3%) for HBV and 2 (4.5%) had both HBV and anti HCV.
The serum AFP level was correlated with tumor size as depicted in from HCC than women due to their tendency to consume more cigarettes, alcohol and tobacco. In our series, men were in a larger proportion in the HCC (predominantly HCV related HCC) than HBV related HCC. The result of this study is similar to findings of study by Abbasi and his co-worker.
5
Early diagnosis of HCC is very important for successful potential treatment. Therefore, regular screening for HCC is recommended for high risk patients, including those with cirrhosis of any etiology, chronic liver disease patients due to HCV infection who had advanced liver disease and chronic HBV patients even without cirrhosis. 6 Some researchers have observed that high AFP levels in cirrhotic as well as viral infected patients precede the development of HCC.7 Combining both strategies i.e. serum AFP and ultrasound imaging every 6-12 months have been preferred as a method of screening for a long time. 7, 8 The optimal frequency and method of surveillance remain debatable. 9 Serum AFP is frequently increased in HCC. Our study revealed 77.8% positivity in HCC cases. AFP positivity among HBV and HCV co-infected and HBV alone HCC cases is 4.4% and 13.3% respectively, while HCV infected HCC cases it is 73.3%. Further, when AFP level were measured in carcinoma patients, the HCC infected group had elevated levels of AFP and we found a significant correlation (p value is < 0.05).
In the present study we have analyzed correlation serum AFP level with the tumor size in HCC. In spite of sub optimal sensitivity AFP is still a valid screening tool for HCC. Our study also shows that majority of patients (77.78%) had raised AFP levels (> 8.5ng/ml). Out of 45 patients 33 (73.33%) were having HCV related to HCC 6 (13.33%) patients were HBV and 2 (4%) patients having both HBV and HCV related HCC. While 4 (18.18%) HCC patients were not HCV and HBV infected. It is mainly due to the high incidence of HCV infection in general population (6-7%) in Pakistan.
In our study majority of patients had a tumor size of more than 5cm i.e Group B and C having 13 (28.8%) and 22 (48.8%) as compared to Group A (10 (22.2%). It shows that if the patients have bigger tumor size there are more chances of raised AFP levels. In present study normal AFP is found in group A (50.0%) and group B (15.4%) and group C (13.7%). This finding is in agreement with other studies. 10, 11 Therefore it is not wise to depend on AFP level alone for assessing tumor size. Finding of sensitive USG should be taken into consideration for tumor size. Local and international data support our findings that there is significant correlation between tumor size and AFP levels in HCC. 12, 13 Our study is in agreement with other studies on AFP levels in patients with HCC and other benign and malignant liver diseases as serum AFP is greater than 400 ng/ml in 69% of patients with hepatoma.
14 A north Indian study showed that 65% of HCC cases have elevated AFP level, The highest level recorded was 580 ng/ml. 15 In another south Indian study, elevated AFP levels were observed in 47.4% of HCC cases. 16 Some clinical researches have suggested that the simultaneous determination of supplementary markers especially glypican-3 along with serum AFP and USG could significantly increase the sensitivity of AFT to detect HCC. 17, 18 However, clinicians should be aware that some patients with primary hepatic cancer could have normal AFP levels, so normal or moderately elevated levels may not be considered a strong evidence to exclude the presence of HCC.
CONCLUSION
This study concludes that there is a significant correlation between serum AFP and tumor size in HCC. Serum AFP progressively increases with tumor size especially in larger size tumors. In spite of suboptimal sensitivity, AFP still proves a beneficial in early diagnosis and screening of HCC, when used in combination of USG/ imaging technique. Copyright© 07 Jan, 2016.
